Effects of radiotherapy and chemotherapy on lung function in patients with non-small-cell lung cancer

被引:57
作者
Gopal, R
Starkschall, G
Tucker, SL
Cox, JDC
Liao, ZX
Hanus, M
Kelly, JF
Stevens, CW
Komaki, R
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Radiat Phys, Houston, TX 77030 USA
[2] Univ Texas, MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA
[3] Univ Texas, MD Anderson Canc Ctr, Dept Biomath, Houston, TX 77030 USA
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2003年 / 56卷 / 01期
关键词
radiotherapy; pulmonary toxicity; lung cancer; diffusion capacity;
D O I
10.1016/S0360-3016(03)00077-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To evaluate the effects of chemoradiation on objective tests of pulmonary function. Methods and Materials: One hundred lung cancer patients treated in five protocols between 1992 and 2000 with combinations of thoracic radiotherapy (RT) and chemotherapy were evaluated with pre- and post-RT pulmonary function tests. The pulmonary function tests were analyzed for changes in measures of obstruction (forced expiratory volume in 1 s per unit of vital capacity [FEV1/VC]), restriction (total lung capacity [TLC]), and diffusing capacity (diffusing capacity for carbon monoxide [DLCO]). The use and timing of chemotherapy and RT, as well as patient, tumor, and treatment factors, were evaluated using univariate and multivariate analyses. Results: No treatment or patient factors were significantly associated with changes in FEV1/VC. Chemotherapy with RT, compared with RT alone, was associated with a lower post-RT TLC (92% vs. 107%,p = 0.002). Nodal status (N2-N3 vs. N1)tumor location (central vs. peripheral), use of greater than or equal to6 treatment fields, and tumor volume greater than or equal to100 cm(3) were also associated with a significantly lower post-RT TLC. On univariate analysis, the use of any chemotherapy (p = 0.029) and the use of concurrent vs. sequential chemotherapy (p = 0.028) were predictive of a lower post-RT DLCO. Patient age greater than or equal to60 years, nodal status (N2-N3 vs. N0-N1), tumor volume greater than or equal to100 cm(3), tumor location (central vs. peripheral), and use of greater than or equal to6 treatment fields were also associated with a significantly lower post-RT DLCO. The fractional volume of irradiated normal lung correlated with the decrease in DLCO (p <0.001), with a 1.3% DLCO decline for each 1% of total lung volume that received >20 Gy. Conclusion: The addition of chemotherapy to RT significantly exacerbates the post-RT decrease in TLC and DLCO. The greatest decrease in DLCO occurs in patients treated with concurrent chemoradiation. (C) 2003 Elsevier Inc.
引用
收藏
页码:114 / 120
页数:7
相关论文
共 38 条
[1]   CONCURRENT RADIATION AND WEEKLY CISPLATIN FOR NON-SMALL-CELL LUNG-CANCER - A PHASE-I PHASE-II STUDY [J].
ABRATT, RP ;
WILLCOX, PA ;
SALTON, DGM .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1992, 30 (06) :495-497
[2]   LATE CARDIOPULMONARY TOXICITY AFTER TREATMENT FOR HODGKINS-DISEASE [J].
ALLAVENA, C ;
CONROY, T ;
ALETTI, P ;
BEY, P ;
LEDERLIN, P .
BRITISH JOURNAL OF CANCER, 1992, 65 (06) :908-912
[3]   LUNG-FUNCTION TESTING - SELECTION OF REFERENCE VALUES AND INTERPRETATIVE STRATEGIES [J].
不详 .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1991, 144 (05) :1202-1218
[4]   Randomized phase III trial of radiation treatment ± amifostine in patients with advanced-stage lung cancer [J].
Antonadou, D ;
Coliarakis, N ;
Synodinou, M ;
Athanassiou, H ;
Kouveli, A ;
Verigos, C ;
Georgakopoulos, G ;
Panoussaki, K ;
Karageorgis, P ;
Throuvalas, N .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2001, 51 (04) :915-922
[5]  
Baltagi B. H., 1985, ECONOMETRIC ANAL PAN
[6]   ESTIMATION OF OVERALL PULMONARY-FUNCTION AFTER IRRADIATION USING DOSE-EFFECT RELATIONS FOR LOCAL FUNCTIONAL INJURY [J].
BOERSMA, LJ ;
DAMEN, EMF ;
DEBOER, RW ;
MULLER, SH ;
OLMOS, RAV ;
VANZANDWIJK, N ;
LEBESQUE, JV .
RADIOTHERAPY AND ONCOLOGY, 1995, 36 (01) :15-23
[7]   Recovery of overall and local lung function loss 18 months after irradiation for malignant lymphoma [J].
Boersma, LJ ;
Damen, EMF ;
deBoer, RW ;
Muller, SH ;
Olmos, RAV ;
vanZandwijk, N ;
Lebesque, JV .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (05) :1431-1441
[8]   Phase III randomized trial of amifostine as a radioprotector in head and neck cancer [J].
Brizel, DM ;
Wasserman, TH ;
Henke, M ;
Strnad, V ;
Rudat, V ;
Monnier, A ;
Eschwege, F ;
Zhang, J ;
Russell, L ;
Oster, W ;
Sauer, R .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (19) :3339-3345
[9]   PULMONARY TOXICITY WITH COMBINED MODALITY THERAPY FOR LIMITED STAGE SMALL-CELL LUNG-CANCER [J].
BROOKS, BJ ;
SEIFTER, EJ ;
WALSH, TE ;
LICHTER, AS ;
BUNN, PA ;
ZABELL, A ;
JOHNSTONEARLY, A ;
EDISON, M ;
MAKUCH, RW ;
COHEN, MH ;
GLATSTEIN, E ;
IHDE, DC .
JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (02) :200-209
[10]  
Capizzi RL, 1999, SEMIN ONCOL, V26, P3